A Phase I Study of Safety and Preliminary Efficacy of YAP101 in Subjects With Ischemic Heart Failure and Reduced Ejection Fraction
Latest Information Update: 06 May 2025
At a glance
- Drugs YAP 101 (Primary)
- Indications Heart failure; Ischaemic heart disorders
- Focus Adverse reactions
- Acronyms SALVADOR-HF
- Sponsors YAP Therapeutics
Most Recent Events
- 27 Apr 2025 Status changed from not yet recruiting to recruiting.
- 25 Feb 2025 New trial record